Patricia A. Bradford is the owner of Antimicrobial Development Specialists LLC, a consulting company that focuses on the late-stage development of antibiotics.

She has previously been responsible for microbiology support at AstraZeneca, where she contributed to the successful development and approval of ceftazidime-avibactam. Before joining AstraZeneca, Patricia worked in antibiotic research for Novartis, Wyeth Pharmaceuticals and Lederle Laboratories. At Wyeth Pharmaceuticals, she worked on several antibiotic projects and was instrumental in the team that wrote the dossier for the registration and approval of tigecycline. She was also heavily involved in the studies for several supplemental new drug applications (sNDA) for piperacillin-tazobactam. She is a fellow in the American Academy of Microbiology and has over 100 publications in peer-reviewed scientific journals and has written several review articles and book chapters. She has served as an editor for Antimicrobial Agents Chemotherapy and is currently a senior editor for mSphere. She is also an active member of the subcommittee on Antimicrobial Susceptibility Testing of the Clinical Laboratory Standards Institute (CLSI).

Patricia completed her PhD in Medical Microbiology at Creighton University, USA and completed a post-doctoral fellowship in the laboratory of Karen Bush in beta-lactamase research.